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The aim of the study is to observe prospectively the
possibility of lowering the cancer risk among BRCA1
carriers by optimizing selenium concentration in diet/
organism. Results of studies performed in several cen-
tres, particularly of our own search, are strongly indi-
cating on potential of decreasing breast/ovarian cancer
risk among carriers by optimization of selenium con-
centration in the body. Studies will be performed on
group of 1500 BRCA1 carriers. Cohort will be
recruited during the first 6 months of the project.
Mean length of follow-up will be 3 yrs. From all
females serum will be collected for selenium analyses-
at the beginning and, then, every 6 months. Partici-
pants will receive the list of products with selenium
concentration estimated according to literature data
and, additionally, information about e-store (http://
www.dietaantyrakowa.pl) specialized in distribution of
food products with defined amount of selenium. Infor-
mation on optimal selenium concentration according
to existing data will be provided also. It is expected
that among ~750 carriers following recommended diet
changes 38 cancers will be diagnosed and among the
others ~750-60. The difference between groups will be
statistically significant with p=0.0278. If necessary,
investigation will be extended.
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